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Abstract 
  
Objective(s) 
The aim of this study was to evaluate the effects of dexamethasone on striatal dopaminergic, glutamatergic 
and gamma amino butyric acid (GABA) ergic neurotransmission in normal and parkinsonian rats. 
Materials and Methods 
Dexamethasone (0.15, 0.30, 0.60 and 0.8 mg/kg) was administered to normal or parkinsonian rats (i.p.) 
followed by the analysis of the striatal neurotransmitters concentrations. Additionally, the effect of 
dexamethasone on the damaged Substantia nigra pars compata (SNc) neurons has been investigated.   
Results 
Dexamethasone resulted in decreased level of striatum glutamatergic-GABAergic and enhanced 
dopaminergic neurotransmission in normal and parkinsonian rats. In addition, acute treatment with 
dexamethasone did not improve the lesion at all.  
Conclusion 
These findings suggest the new therapeutic mechanism of action for dexamethasone in Parkinson’s disease 
animal model. 
 
Keywords: Dexamethasone, Dopamine, GABA, Glutamate, Parkinson’s disease  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1- Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran 
2- R and D and QC consultant & Hepatitis and AIDS Department, Research and Production Complex, Pasteur Institute 
of Iran, Tehran, Iran  
3- Department of Physiology and Physiology Research Center, Jundishapour University of Medical Sciences, Ahvaz, Iran 
4- Department of Genetics, Shahid Beheshti University of Medical Sciences, Tehran, Iran 
* Corresponding author: Tel/Fax: +98-021-66953311; email: shafieeardestani@gmail.com  
Massoud Amanlou et al 
          Iran J Basic Med Sci, Vol. 14, No. 2, Mar-Apr 2011  108 
Introduction 
Parkinson’s disease (PD) is a neurodegenerative 
brain disease in the nigrostriatal pathway of 
animals or humans. The resulting losses of nerve 
terminals accompanied by dopamine deficiency 
in this signaling pathway are responsible for 
most of the movement disorders affiliated to the 
disease. Its prevalence or incidence rates 
increase with age, and more than 2% of the 
population aged over 60 years and ~ 10–
20/100,000 individuals per year are affected by 
PD. Its diagnosis is based on medical history and 
a neurological examination, and can be difficult 
to be proven accurately. Neurodegeneration 
decreases dopaminergic content in both 
Substantia Nigra and striatum, which has been 
ascertained by several neuroimaging evidences. 
The reduction of 
18 F-fluoro-L- Dopa, 
99mTc-
TRODAT-1, dopamine presynaptic transporter 
radioligands, and 
18 F-CIT/FCCIT in the striatum 
has been demonstrated using positron emission 
tomography (PET) and single photon emission 
computed tomography (SPECT) scanning (1, 2). 
Novel  evidences  suggest  more  important          
roles for inflammatory reactions accompanying 
the pathological processes seen in many 
neurodegenerative  disorders,  including                 
PD  (2,  3).  Cyclooxygenase  (COX)  is  the             
first enzyme in the     
prostaglandin/prostacyclin/thromboxane athway 
and plays an important role in inflammatory 
systems. It converts arachidonic acid to 
prostaglandins and thromboxanes, which are 
collectively known as its metabolites (4). Three 
COX isoenzymes, COX- 1, COX-2, and COX-3 
(a splice variant of COX-1, which retains intron 
one and has a frameshift mutation; thus some 
prefer the name COX-1b or COX-1 variant 
(COX-1v)) have been identified (5, 6). COX-1 is 
the constitutive form of COX, and performs a 
housekeeping function to synthesize 
prostaglandins, which are involved in regulating 
normal cellular activities (7). In contrast, COX-2 
is the inducible form of COX, as its expression 
can be induced by inflammatory stimuli or 
mutagens, tumor necrosis factor alpha (TNF-α) 
and the transcription factor CCAAT enhancer 
binding protein (c/EBP) beta. On the other hand, 
COX converts arachidonic acid (AA, an ω-6 
PUFA) to prostaglandin H2 (PGH2), the 
precursor of the series-2 prostanoids. The 
enzyme contains two active sites: a heme with 
peroxidase activity, responsible for the reduction 
of PGG2 to PGH2, and a cyclooxygenase site, 
where arachidonic acid is converted into the 
hydroperoxy endoperoxide prostaglandin G2 
(PGG2). The reaction proceeds through H atom 
abstraction from arachidonic acid by a tyrosine 
radical generated by the peroxidase active site. 
Two O2 molecules then react with the 
arachidonic acid radical, yielding PGG. 
Among the COX isoenzymes, just COX-2 
corresponds to inflammatory and degenerative 
brain disease (5). PD is a degenerative 
neurodopaminergic disease in nigrostriatum 
pathway of human and the resultant loss of 
nerve terminals accompanied by dopamine 
deficiency in this pathway are responsible for 
most of the movement disorders (6). 
Increasing evidence suggests that an 
inflammatory reaction accompanies the 
pathological processes seen in many 
neurodegenerative disorders, including PD. 
In fact, COX-2 is upregulated during 
stressful conditions such as cerebral ischemia 
and is also upregulated by neuronal apoptosis 
and neurobehavioral defects (8, 9). In addition, 
the steroidal anti-inflammatory drugs such as 
dexamethasone can inhibit COX-2 gene 
expression; the glucocorticoids have 
widespread effects because they influence in 
the function of most cells in the body. 
Glucocorticoids dramatically reduce the 
manifestations of inflammation. This is due to 
their profound effects on the concentrations, 
distribution, and function of peripheral 
leukocytes and to their suppressive effects on 
the inflammatory cytokines such as TNF-α, 
interleukin-6 (IL-6), and chemokines on other 
lipid and glucolipid mediators of 
inflammation. In addition to their effects, 
glucocorticoids influence the inflammatory 
response by reducing the prostaglandin 
synthesis that results from activation of 
phospholipase A2 (3-9). 
Hence, steroidal anti-inflammatory drugs 
such as dexamethasone can inhibit COX-2 
gene expression or possible COX-2 
upexpressing agents such as TNF-α or 
CCAAT significantly. Neuroscientists propose  
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that COX-2 corresponds to inflammatory and 
degenerative brain disease (10). In cell 
cultures and animal models, inflammation 
contributes  to  the  neuronal  damage,  and           
anti-inflammatory agents such as 
dexamethasone or celecoxib have been shown 
to provide some neuroprotection in animal 
models of PD (11, 12). Confirming previous 
studies, administration of steroidal anti-
inflammatory drugs (SAIDs) causes the same 
neuroprotection effects similar to non-steroidal 
anti-inflammatory drugs (NSAIDs) in PD 
animal models (13) and also in treatment of 
PD signs such as rigidity (14, 15). 
Furthermore, the anti-inflammatory 
properties of glucocorticoids are the main 
reason why they have clinical applications. 
Many conditions have some component of 
inflammation as part of their pathophysiology. 
By  administering  synthetic  versions  of           
these hormones (e.g., prednisone and 
methylprednisolone) orally or through some 
other routes, the condition can be better 
managed. 
Many of these conditions are autoimmune 
diseases or inflammatory conditions with 
unknown causes. They include, but are not 
limited to, Crohn's disease, ulcerative colitis, 
systemic lupus erythematosus (SLE), and 
rheumatoid arthritis. Glucocorticoids can also 
be administered for chronic obstructive 
pulmonary disease (COPD), immune 
suppression following organ transplantation, 
and cortisol deficiency secondary to disease in 
the pituitary gland or adrenal glands (e.g., 
Addison's disease). 
  The study of striatal dopaminergic, 
glutaminergic or GABAergic interactions has 
special importance due to the physiological 
and pathophysiological processes of these 
systems, such as Parkinson's or Huntington's 
diseases (14). The critical roles of 
dopaminergic, glutamatergic, and GABAergic 
neurotransmissions and their well known 
interactions in the nigrostriatal pathway and 
PD led to the some studies such as in vivo 
assays of dopamine, glutamate, and GABA 
after administration of dexamethasone in 
normal and PD rat models to investigate the 
underlying mechanisms for the previously 
reported improving effect of dexamethasone 
on PD rigidity (14). 
 
Methods 
Chemicals 
Dexamethasone, ketamine, and xylazin were 
purchased from Merck (Germany). 
Dexamethasone dissolved freely in dimethyl 
sulfoxide (DMSO), and ketamine and xylazin 
dissolved in distilled water.  
 
Animals 
Male albino Wistar rats (200-250g) were the 
subjects of the present study. They were 
housed in groups of eight in stainless steel 
cages, handled daily and provided with food 
and water ad libitum. A 12 hr light/12 hr dark 
cycle was maintained, and the animals were 
tested during the light cycle. These 
experiments were carried out in accordance 
with the recommendations from the 
declaration of Helsinki and the internationally 
accepted principles in the use of experimental 
animals. In this study each group contained 
eight rats (8 animals/group). 
 
Surgery 
Each rat was anesthetized separately by 
injection of 75 mg/kg ketamine combined with 
8 mg/kg xylazin i.p. Then, the rats were placed 
in the stereotaxic instrument. The left 
substantia nigra pars compacta (SNc) region of 
the nigrostriatum was targeted at the following 
coordinates: -4.8 mm posterior and -1.6 mm 
lateral to bregma and 8.2 mm ventral to the 
surface of the skull for the left SNc according 
to the atlas (16) Vehicle (0.2% ascorbic acid). 
For non-control rats, 6-hydroxy dopamine (6-
OHDA) (8 µg in 1 µl in 0.2% ascorbic acid) 
was infused unilaterally through a 26-gauge 
stainless steel cannula into the SNc region in 
order to create hemiparkinsonian rats. Then, 
the skull was exposed and a hole was drilled 
through it in the area overlying the right 
striatum, using the following coordinates with 
respect to the bregma: A/P + 1 mm; M/L + 3 
mm, D/V + 6 mm according to the atlas (16). 
A guide-cannula lowered into the brain was 
fixed to the cranium and the incision was 
closed. Rats were allowed to recover from the 
surgery for 7–10 days.   
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Microdialysis procedure 
Microdialysis experiments were performed both 
in normal and SNc-lesioned animals. A 
microdialysis probe was inserted into the 
cannula, and the inputs of the probes were 
connected to a microperfusion pump CMA/102 
infusion pump (CMA/Microdialysis, Sweden), 
which delivered a modified Ringer solution (147 
mM NaCl, 1.2 mM CaCl2, 2.7 mM KCl, 1.0 
mM MgCl2 and 0.04 mM ascorbic acid) through 
the probe at a flow rate of 2 µl/min. Ringer 
solution was then infused for 3–3.5 hr before the 
baseline samples were collected to obtain stable 
basal extracellular levels of dopamine, 
glutamate, and GABA. The microdialysate 
samples (20 µl) were collected every 20 min and 
the dialysates were collected for 4 hr. The stress 
caused by the i.p. vehicle injection, catalepsy 
evaluation and handling of the rats was not 
found to alter the extracellular GABA-
glutamate-dopamine levels. Microdialysate 
levels of glutamate-GABA and dopamine were 
analyzed immediately using reverse-phase high 
performance liquid chromatography (HPLC). 
 
Histological study 
After the experiments, recovery of damaged SNc 
neurons was evaluated using the histological 
studies by preparation of 50 µm coronal brain 
sections as previously described
 (14). In addition, 
the location of the probe was determined 
histologically on serial coronal sections. Only 
data obtained from rats with correctly implanted 
probes were included in the results.  
  
HPLC conditions 
The electrochemical detection (ECD) system   
used for dopaminergic determination consisted 
of a Shimadzu SCL 10-Avp system controller, 
LC-10AS pump, SIL-10A cooled autoinjector, 
CT0-10A oven, LECD-6A electrochemical 
detector and a Gastorr online degasser (ISS, 
England). System components were used in 
conjunction with Class VP-5 software 
(Shimadzu). All samples were injected into a 
reversed phase Luna 5  µ C18 (2) 
250 mm × 4.6 mm  column  (Phenomenex), 
which was protected by Krudkatcher 
disposable pre-column filters (Phenomenex) 
and SecurityGuard cartridges (Phenomenex).  
The fluorescent detection (FLD) system 
using for GABA-glutamate determination 
consisted of a Waters 510 pump, 717plus 
cooled Autosampler, a Hewlett Packard 1046A 
fluorescent detector, a Waters busSAT/IN 
module and a Croco-Cil column oven. System 
components were used in conjunction with 
Waters Empower software. All samples were 
injected into a reversed phase Luna 3 µ C18 
(2)  150 mm × 2 mm  column,  which  was 
protected by Krudkatcher disposable pre-
column filter and SecurityGuard cartridges.  
The mobile phase that was used in the ECD 
system was composed of a mixture of 0.1 M 
di-sodium hydrogen orthophosphate/50  µM 
EDTA (pH 5.4, 1 M OPA) and HPLC grade 
methanol (36:64). Mobile phase was filtered 
through Millipore 0.45  µm and vacuum 
degassed prior to use. Compounds were eluted 
isocratically over a 20 min runtime at a flow 
rate of 0.60 ml/min after a 20 µl injection. The 
column was maintained at a temperature of 
30 °C and samples/standards were kept at 4 °C 
in the cooled autoinjector prior to analysis 
unless otherwise stated. The glassy carbon 
working electrode combined with an Ag/AgCl 
reference electrode (Shimadzu) was performed 
at +0.8  V unless otherwise specified and the 
range of the detector was set to 1.  
The  mobile  phase  which  was  used                  
on the FLD system was composed of a   
mixture of 0.1  M di-sodium hydrogen 
orthophosphate/50  µM EDTA (pH 5.4, 1  M 
OPA) and HPLC grade methanol (30:70). 
Mobile phase was filtered through Millipore 
0.45  µm and vacuum degassed prior to use. 
Compounds were eluted isocratically over a 
15  min runtime at a flow rate of 0.1  ml/min 
after a 20  µl injection. The column was 
maintained at a temperature of 30  °C and 
samples/standards were kept at 4  °C in the 
cooled autoinjector prior to analysis unless 
otherwise stated. The fluorescent detector was 
set at an excitation wavelength of 420 nm, an 
emission wavelength of 480 nm and a PMT gain 
of 5. GABA/glutamate was identified by their 
specific retention times as determined by 
standard injections which were run at regular 
intervals during sample analysis. Sample peak 
heights were measured and compared with  
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standard injections in order to quantify the 
amino acids. 
 
Statistical analysis 
The results (described next) are shown as the 
mean±SEM relative to the basal levels, for 7-8 
animals/group. The average concentration of 
three stable samples from control rats (receiving 
no drug or vehicle) was considered as the basal 
levels. Statistical evaluation of the results was 
performed using one-way analysis of variance 
(ANOVA) and Student–Newman–Keuls 
multiple range test, considering the following 
significant differences: P< 0.05.  
 
Results 
Mean values for striatal extraneuronal (i.e. 
microdialysate) concentrations of glutamate in 
normal and parkinsonian rats before drug-
vehicle injection (baseline) were 2.3±0.25 
(normal rats) and 2.82±0.35 (parkinsonian rats) 
ng/20 µl. Mean values for dopamine 
concentrations were determined as 3.16±0.51 
(normal) and 2.1±0.35 pg/20 µl (parkinsonian 
rats), as well as GABA concentrations 
0.129±0.02 ng/20 µl (normal rats) and 
0.391±0.06 ng/20 µl (parkinsonian rats) 
respectively. Varying doses of dexamethasone 
were observed to change (significantly or not) 
GABAergic, glutamatergic and dopaminergic 
neurotransmission in the striatum of normal or 
parkinsonian rats within the observation period, 
as depicted in Figure 1. In particular, upon 
injection of 0.8 mg/kg of dexamethasone, the 
aforementioned numbers (now averaged 
from 40-180 min after injection) changed to: 
(glutamate) 1.78±0.12 and 2.17±0.12 ng/20 µl, 
(dopamine) 3.54±0.23 ng/20 µl and 3.14±0.21 
pg/20  µl,  and  (GABA)  0.103±0.07  ng/20  µl                   
and 0.121±0.03 ng/20 µl, respectively. The 
changes caused by dexamethasone on the striatal 
neurotransmissions of normal or parkinsonian 
rats indicated that: (i) Significant increase in 
dopaminergic neurotransmission of parkinsonian 
rats was observed during the 60 and 140-180 
min comparing to normal rats. Furthermore, 
significant decrease in glutamatergic 
neurotransmission was observed during the 140-
180 period (comparing normal and treated 
levels). According to the results, a significant 
decrease in GABAergic neurotransmission 
during the 40-60 (caused by dexamethasone 0.8 
mg/kg) and 140-180 (caused by dexamethasone 
0.6 mg/kg) periods, comparing the normal and 
treated parkinsonian rats' levels were noticed and 
the result is presented in Figure 1A-C. (ii) All 
normal rats that received dexamethasone (0.6 
and  0.8  mg/kg)  were  shown  a  significant            
(P< 0.05) increase in dopaminergic (40-140 
min) and decrease in GABAergic (20-80 min, 
caused by dexamethasone 0.8 mg/kg and 60-
180, caused by dexamethasone 0.6 mg/kg) as 
well as glutamatergic (40-140 min for 0.8 mg/kg 
or 80-120 min, caused by dexamethasone 0.6 
mg/kg) neurotransmission. The corresponding 
data are shown in Figure1 D-F. 
Histological results did not show any significant 
improvement in the damaged SNc neurons 
resulting from administration of dexamethasone 
at all (Figure 2).  
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Figure 1. Mean values for striatal (A) dopaminergic, (B) glutamatergic and (C) GABAergic neurotransmission in parkinsonian 
rats after administration of various doses of dexamethasone. Corresponding results for normal rats are shown in (D), (E) and (F) 
respectively. The neurotransmission changes in parkinsonian rats caused by dexamethasone were observed to be more significant 
than normal rats. The significant marker * indicates a significant difference P< 0.05 comparing to PD control group.  
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Figure 2. A: Microscopic magnification (4X) of the SNc 
neurons  in  normal  rats.  B:  Destroyed  SNc  before           
any treatment due to 6OHDA administration.                            
C: Dexamethasone did not improve the damaged 
neurons caused by 6OHDA at all. 
 
Discussion 
This study was intended to explore the important 
mechanisms of action for dexamethasone as a 
steroid in glutamatergic, GABAergic and 
dopaminergic neurotransmission in the striatum 
of normal and parkinsonian rats. Additionally, 
this study showed that acute dexamethasone 
administration did not have any improving effect 
on damage SNc. 
It is reported that inflammation and its 
mediators such as prostaglandins (PGs) have 
an important role in neurotransmitter release 
(12, 14).
  These reports suggested that 
inflammation causes increased levels of 
acetylcholine in the brain via production of 
PGE2 and increases in expression of 
cholinergic markers, such as choline acetyl 
transfrase and vesicular acetylcholine 
transporter protein. It was also reported that 
prostaglandins have modulatory effects on 
adrenergic, noradrenergic and glutaminergic 
transmission, specially PGE2, and 
prostaglandin synthesis inhibitors induced 
increases in the blood pressure via increases in 
the release of the catecholamine; for example 
using large doses of glucocorticoids in humans 
may cause insomnia, euphoria and increase the 
intracranial pressure (14, 17).  
Moreover, glucocorticoids, namely cortisol, 
have multiple functions related to metabolism 
and regulation. They raise blood glucose levels 
through breakdown of fat and muscle protein, 
increasing insulin resistance in tissues, and 
other processes. They also inhibit bone 
formation, raise the blood pressure, and 
suppress inflammatory processes as part of 
their additional regulatory function. Stress is a 
major cause of glucocorticoids release.  
Another line of evidence suggests that 
parkinsonian patients when confronted with a 
stressful event are able to overcome their 
immobility for a short period of time. This is 
proposed to be due to a release of 
catecholamines from adrenal medulla or 
activation of central sympathetic noradrenergic 
neurons. It has been also reported that 
glucocorticoids can increase adrenaline 
production by exerting a stimulatory action on 
two of the enzymes that regulate 
catecholamine synthesis viz. tyrosine 
hydroxylase (the rate limiting enzyme) and 
phenylethanolamine  N-methyl  transferase         
(6-9, 11, 15, 16). One of the other proposed 
mechanism for the above observations is 
regarding to neuronal COX-2 over gene 
expression which may kill neurons in a cell-
autonomous manner and leads to pathogenic 
hypothesis for PD (17-20). It also suggests that 
COX-2 cell-autonomous toxicity may arise 
from the formation of reactive oxygen species 
generated during COX peroxidase catalysis of 
prostaglandin G2 conversion to prostaglandin 
H2. Electron donation to COX facilitates 
dopamine oxidation to dopamine-quinone. In 
PD, there is evidence of an increased level of  
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oxidative and inflammatory nigral environment 
that includes the presence of (COX)-
immunoreactive activated microglial cells in the 
substantia nigra. Microglial cells can also 
produce and release pro-inflammatory cytokines, 
in particular TNF-α and cytotoxic molecules 
including ROS and NO. These may inhibit 
neurotransmission release in striatum region. 
Dexamethasone probably protects these events 
and increases dopamine release which can also 
act as a key point in the recovery pathway of PD.  
The results were also in confirmation with 
previously published literatures showing that 
COX-2 nor COX-1 or COX-2 gene expression 
inhibition did not repair SNc damaged neurons 
acutely or chronically (14, 17). 
The above observations show a good 
therapeutic potential for dexamethasone in PD 
signs recovery. It should be added that in the 
literature there are some explanations for 
neuronal damage caused by corticosteroids. It 
has been shown repeatedly that under certain 
conditions glucocorticoids
 exacerbate different 
types of neurological defects (2-4).
  As the 
hippocampus is a major target for neuronal 
degeneration in
 the brains of patients with AD, 
and as it is richly endowed
 with GRs, it is also 
a principal target site for glucocorticoids.   
Neurotoxic challenges induced by
  the 
oxidative stressors Aß and glutamate, two 
neurotoxins
 that have been implicated in AD 
(6-9, 11, 15, 16, 18-20), are
  enhanced by 
pretreatment of the hippocampal neurons with 
glucocorticoids. However, in controversy of 
our results (acute study) it should be stated that 
there is evidence that steroidal compounds like 
dexamethasone can protect dopaminergic 
neurons against PD (18-20). Indeed, that was a 
chronic study and it is possible that the 
difference observed due to mentioned above- 
reasons.  
Further experiments are necessary in order to 
clarify the role of anti inflammatory agents 
such as dexamethasone in other striatal 
neurotransmissions. 
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